Callahan Advisors’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $440K | Buy |
3,156
+4
| +0.1% | +$560 | 0.04% | 138 |
|
|
2025
Q4 | $387K | Buy |
3,152
+5
| +0.2% | +$608 | 0.03% | 143 |
|
|
2025
Q3 | $349K | Buy |
3,147
+5
| +0.2% | +$568 | 0.03% | 136 |
|
|
2025
Q2 | $348K | Sell |
3,142
-1,506
| -32% | -$160K | 0.03% | 136 |
|
|
2025
Q1 | $521K | Sell |
4,648
-1,892
| -29% | -$195K | 0.05% | 125 |
|
|
2024
Q4 | $604K | Buy |
6,540
+3,415
| +109% | +$307K | 0.06% | 125 |
|
|
2024
Q3 | $262K | Sell |
3,125
-994
| -24% | -$75.8K | 0.03% | 130 |
|
|
2024
Q2 | $283K | Buy |
4,119
+1,008
| +32% | +$67.3K | 0.03% | 128 |
|
|
2024
Q1 | $228K | Buy |
3,111
+8
| +0.3% | +$615 | 0.02% | 137 |
|
|
2023
Q4 | $251K | Buy |
3,103
+6
| +0.2% | +$467 | 0.03% | 129 |
|
|
2023
Q3 | $232K | Buy |
3,097
+7
| +0.2% | +$538 | 0.03% | 132 |
|
|
2023
Q2 | $238K | Sell |
3,090
-493
| -14% | -$39.3K | 0.03% | 128 |
|
|
2023
Q1 | $297K | Sell |
3,583
-144
| -4% | -$11.9K | 0.04% | 126 |
|
|
2022
Q4 | $320K | Buy |
3,727
+27
| +0.7% | +$2.14K | 0.04% | 122 |
|
|
2022
Q3 | $228K | Buy |
3,700
+9
| +0.2% | +$568 | 0.03% | 136 |
|
|
2022
Q2 | $228K | Buy |
3,691
+9
| +0.2% | +$557 | 0.03% | 138 |
|
|
2022
Q1 | $219K | Buy |
+3,682
| New | +$235K | 0.03% | 142 |
|
|
2021
Q4 | – | Sell |
-2,865
| Closed | -$200K | – | 150 |
|
|
2021
Q3 | $200K | Buy |
+2,865
| New | +$201K | 0.03% | 144 |
|
|
2021
Q1 | – | Sell |
-3,843
| Closed | -$224K | – | 143 |
|
|
2020
Q4 | $224K | Buy |
3,843
+207
| +6% | +$12.5K | 0.03% | 134 |
|
|
2020
Q3 | $230K | Sell |
3,636
-628
| -15% | -$43.5K | 0.04% | 125 |
|
|
2020
Q2 | $328K | Sell |
4,264
-359
| -8% | -$27.5K | 0.06% | 106 |
|
|
2020
Q1 | $346K | Sell |
4,623
-595
| -11% | -$41.1K | 0.07% | 97 |
|
|
2019
Q4 | $339K | Sell |
5,218
-494
| -9% | -$32.2K | 0.05% | 111 |
|
|
2019
Q3 | $362K | Sell |
5,712
-934
| -14% | -$61.1K | 0.06% | 109 |
|
|
2019
Q2 | $449K | Sell |
6,646
-2,694
| -29% | -$177K | 0.08% | 107 |
|
|
2019
Q1 | $607K | Sell |
9,340
-16,244
| -63% | -$1.08M | 0.11% | 98 |
|
|
2018
Q4 | $1.6M | Sell |
25,584
-2,895
| -10% | -$202K | 0.34% | 61 |
|
|
2018
Q3 | $2.2M | Sell |
28,479
-53,497
| -65% | -$4.04M | 0.41% | 61 |
|
|
2018
Q2 | $5.81M | Sell |
81,976
-4,065
| -5% | -$287K | 1.14% | 34 |
|
|
2018
Q1 | $6.49M | Buy |
86,041
+2,393
| +3% | +$190K | 1.33% | 32 |
|
|
2017
Q4 | $5.99M | Sell |
83,648
-6,408
| -7% | -$487K | 1.19% | 36 |
|
|
2017
Q3 | $7.3M | Buy |
90,056
+7,297
| +9% | +$558K | 1.53% | 31 |
|
|
2017
Q2 | $5.86M | Buy |
82,759
+3,731
| +5% | +$248K | 1.28% | 36 |
|
|
2017
Q1 | $5.37M | Sell |
79,028
-19,634
| -20% | -$1.38M | 1.21% | 34 |
|
|
2016
Q4 | $7.07M | Sell |
98,662
-2,058
| -2% | -$153K | 1.7% | 26 |
|
|
2016
Q3 | $7.97M | Buy |
100,720
+9,178
| +10% | +$746K | 1.99% | 19 |
|
|
2016
Q2 | $7.64M | Buy |
91,542
+768
| +0.8% | +$68.2K | 2.01% | 18 |
|
|
2016
Q1 | $8.34M | Buy |
90,774
+5,282
| +6% | +$476K | 2.29% | 10 |
|
|
2015
Q4 | $8.65M | Buy |
85,492
+4,229
| +5% | +$440K | 2.47% | 10 |
|
|
2015
Q3 | $7.98M | Buy |
81,263
+1,467
| +2% | +$163K | 2.45% | 6 |
|
|
2015
Q2 | $9.34M | Buy |
79,796
+2,360
| +3% | +$258K | 2.69% | 2 |
|
|
2015
Q1 | $7.6M | Buy |
77,436
+5,276
| +7% | +$536K | 2.21% | 5 |
|
|
2014
Q4 | $6.8M | Sell |
72,160
-1,178
| -2% | -$122K | 2% | 8 |
|
|
2014
Q3 | $7.81M | Buy |
73,338
+142
| +0.2% | +$13.9K | 2.42% | 5 |
|
|
2014
Q2 | $6.07M | Buy |
73,196
+9,871
| +16% | +$768K | 1.93% | 9 |
|
|
2014
Q1 | $4.49M | Sell |
63,325
-4,140
| -6% | -$325K | 1.53% | 26 |
|
|
2013
Q4 | $5.07M | Sell |
67,465
-1,305
| -2% | -$90.9K | 1.77% | 14 |
|
|
2013
Q3 | $4.32M | Buy |
68,770
+1,240
| +2% | +$74.1K | 1.65% | 18 |
|
|
2013
Q2 | $3.46M | Buy |
+67,530
| New | +$3.52M | 1.42% | 30 |
|
Other funds holding GILD
VCM
VPM
Callahan Advisors's GILD Position: Q1 2026 in Review
Callahan Advisors increased its Gilead Sciences (GILD) stake by 0.13% in Q1 2026, buying an estimated $560 and bringing the position to 3,156 shares worth $440K. The position accounts for 0.04% of the portfolio, ranked #138.
Callahan Advisors first reported a position in GILD in Q2 2013 and has held it in 49 quarters since. The position peaked at $9.34M in Q2 2015. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.
- Callahan Advisors held 3,156 shares of Gilead Sciences worth $440K as of Q1 2026.
- Callahan Advisors bought 4 Gilead Sciences shares in Q1 2026, an estimated $560.
- Gilead Sciences made up 0.04% of Callahan Advisors's portfolio in Q1 2026, its #138 holding.
- Callahan Advisors first reported a position in Gilead Sciences in Q2 2013 and has held it in 49 quarters since.
- Callahan Advisors's Gilead Sciences position peaked at $9.34M in Q2 2015.
- 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.
Based on Callahan Advisors's 13F filing for Q1 2026, filed 12 May 2026.